Posted by Michael Wonder on 15 Jul 2020
Improving clinical trial enrollment — In the COVID-19 era and beyond
15 July 2020 - More than 3 million people in the United States are known to have been infected with SARS-CoV-2.
If every study registered on clinicaltrials.gov as of mid-June meets its target enrolment, less than 4% of those diagnosed with COVID-19 will have been enrolled in a randomised, controlled trial.
In the face of a new disease in dire need of proven treatments, every patient not offered enrolment in a well-designed, well-conducted study represents a missed opportunity to advance scientific knowledge, develop therapeutic strategies, and ultimately improve care for everyone who will come next.
